177Lu-PSMA radio-ligand therapy

被引：0
|
作者：
Chanchou, M. [1 ]
Giraudet, A. L. [2 ]
机构：
[1] UCA, Serv Med Nucl,Inserm, Ctr Jean Perrin, UMR 1240,IMoST, 58 Rue Montalembert, F-63011 Clermont Ferrand, France
[2] Ctr Leon Berard, Serv Med Nucl, Lyon, France
来源：
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2023年 / 47卷 / 06期
关键词：
Lu-177-PSMA; RLT; PSMA-PET; MCRPC; RESISTANT PROSTATE-CANCER; TRIAL;
D O I：
10.1016/j.mednuc.2023.09.005
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Lutetium-177-labeled PSMA radio-ligand therapy is becoming more and more widespread in nuclear medicine departments, in France and around the world. Practitioners must master specificities of this treatment in order to develop this type of therapeutic care in the best conditions. This summary article presents the methods of carrying out treatment with Lu-177-PSMA in nuclear medicine departments as well as the various current clinical research subjects concerning this theme. (C) 2023 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：316 / 322
页数：7
相关论文
共 50 条
  • [21] Pre- or Post-Chemotherapy: Effect of 177Lu-PSMA Radioligand Therapy on PSMA Expression
    Yadav, Surekha
    Heath, Courtney Lawhn
    Juarez, Roxanna
    De Kouchkovsky, Ivan
    Aggarwal, Rahul
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [22] Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
    Kwekkeboom, Dik
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) : 1002 - 1003
  • [23] Evaluation of the contamination risk during 177Lu-PSMA therapy of advanced prostate cancer
    Brosch-Lenz, Julia
    Nekolla, Stephan
    Tischendorf, Luisa
    Allmann, Jakob
    Weber, Wolfgang
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [24] Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid
    Simsek, Duygu Has
    Kuyumcu, Serkan
    Agaoglu, Fulya Yaman
    Unal, Seher Nilgun
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 764 - 766
  • [25] Comparison of 68Ga-PSMA and 177Lu-PSMA Total Metabolic Tumor Volume (TMTV) variations for monitoring metastatic castration-resistant prostate cancer in 177Lu-PSMA therapy.
    Boursier, C.
    Zaragori, T.
    Kunsch, J.
    Olivier, P.
    Claudin, M.
    Marie, P.
    Bros, M.
    Bordonne, M.
    Verger, A.
    Karcher, G.
    Imbert, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S361 - S362
  • [26] Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA A Chance for 177Lu-DOTATATE Therapy?
    Nesari Javan, Farnaz
    Aryana, Kamran
    Askari, Emran
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : E480 - E482
  • [27] Influence of patient motion on image-based dosimetry for 177Lu-PSMA therapy
    Resch, S.
    Rumiantcev, M.
    Liubchenko, G.
    Brendel, M.
    Ziegler, S. I.
    Boening, G.
    Delker, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S211 - S211
  • [28] Insights into treatment optimization: Mathematical modeling of tumor growth in 177Lu-PSMA therapy
    Zaid, Nouran
    Bastiaannet, Remco
    Hobbs, Robert
    Sgouros, George
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [29] Semi-automatic Segmentation of Metastatic Tumor Load for 177Lu-PSMA Therapy
    Parhi, Subhadarshini
    Xue, Song
    Gafita, Andrei
    Eiber, Matthias
    Rominger, Axel
    Afshar-Oromieh, Ali
    Shi, Kuangyu
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [30] Evaluation of radiation safety in 177Lu-PSMA therapy and development of outpatient treatment protocol
    Demir, Mustafa
    Abuqbeitah, Mohammad
    Uslu-Besli, Lebriz
    Yildirim, Ozlem
    Yeyin, Nami
    Cavdar, Iffet
    Vatankulu, Betul
    Gunduz, Huseyin
    Kabasakal, Levent
    JOURNAL OF RADIOLOGICAL PROTECTION, 2016, 36 (02) : 269 - 278
12345